Schering-Plough's Claritin nonsedating antihistamine approved for urticaria Sept. 20.
Executive Summary
SCHERING-PLOUGH's CLARITIN GAINS URTICARIA INDICATION, FDA informed the company Sept. 20 in responding to its supplemental NDA filed Feb. 14, 1994. Claritin (loratadine) is the second nonsedating antihistamine approved for idiopathic chronic urticaria (hives). Johnson & Johnson's Hismanal (astemizole) is also indicated for urticaria.